TGF-Beta-Activated Cancer-Associated Fibroblasts Limit Cetuximab Efficacy in Preclinical Models of Head and Neck Cancer

TGF-Beta-Activated Cancer-Associated Fibroblasts Limit Cetuximab Efficacy in Preclinical Models of Head and Neck Cancer

Most head and neck cancer (HNC) patients are resistant to cetuximab, an antibody against the epidermal growth factor receptor. Such therapy resistance is known to be mediated, in part, by stromal cells surrounding the tumor cells; however, the mechanisms underlying such a resistance phenotype remain...

Full description

Bibliographic Details
Main Authors: Ksenia M. Yegodayev, Ofra Novoplansky, Artemiy Golden, Manu Prasad, Liron Levin, Sankar Jagadeeshan, Jonathan Zorea, Orr Dimitstein, Ben-Zion Joshua, Limor Cohen, Ekaterina Khrameeva, Moshe Elkabets
Format: Article
Language:English
Published: MDPI AG 2020-02-01
Series:Cancers
Subjects:
head and neck cancer
cancer-associated fibroblast
cetuximab
tumor microenvironment
therapy resistance
Online Access:https://www.mdpi.com/2072-6694/12/2/339

Internet

https://www.mdpi.com/2072-6694/12/2/339

Similar Items